Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the Lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast. Therefore, the D3G of the present invention is expected to be useful as a pharmacological agent or functional food effective for the prevention and treatment of osteoporosis which is a disease caused by the abnormal balance of bone remodeling.
Type:
Grant
Filed:
March 2, 2016
Date of Patent:
December 28, 2021
Assignee:
DONG WOO DANG CO., LTD
Inventors:
Dam Huh, Seon-Yong Jeong, Eunkuk Park, Moon-chang Kim, Ji Won Lee, Jeong Hyun Kim
Abstract: Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.
Type:
Grant
Filed:
March 1, 2017
Date of Patent:
March 12, 2019
Assignee:
DONG WOO DANG CO., LTD
Inventors:
Seon-Yong Jeong, Si Young Yang, Eun Kuk Park, Jeong Hyun Kim, Mun-Chang Kim
Abstract: The present invention relates to a compound of dihydrophaseic acid 3?-O-beta-D-glucopyranoside for the prevention and treatment of osteoporosis. It was found that the D3G isolated from the lycium root bark extract induces the activity of osteoblast differentiation while promoting the proliferation of pre-osteoblast, and promotes the bone remodeling by promoting the differentiation of both osteoblast and osteoclast when mixing and culturing pre-osteoblast which is the precursor of osteoblast, and monocyte which is the precursor of osteoclast.
Type:
Application
Filed:
March 2, 2016
Publication date:
August 2, 2018
Applicants:
DONG WOO DANG CO., LTD, Ajou University Industry-Academic Cooperation Foundation
Inventors:
Dam Heo, Seon Yong Jeong, Eun-guk Park, Moon-chang Kim, Ji Won Lee, Jeong Hyun Kim